Full video transcriptClick to expand
Auto-generated transcript of @lose.weight.with.kate's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00So the NAD injections that I'm taking were recommended to be done intermuscular.
- 0:04The instructions that they came with said that you could do either intermuscular or sub-Q.
- 0:10I've been doing my GLP1 injection sub-Q so I was definitely more comfortable doing it that way so
- 0:16that's how I'm going to start off doing the NAD injections and then eventually I might switch
- 0:22to intermuscular. I've definitely heard that they're more effective that way but doing them sub-Q I've
- 0:27already noticed the difference so I'm cool doing that for now. The IVs are here are definitely the
- 0:32best way to do it but they're extremely expensive and very inconvenient. I'm pretty sure that's how
- 0:39all the celebrities do them but I don't have that celebrity money so I'm cool with the injections.
NAD+ injections for energy and aging: what the evidence shows
Quick answer
NAD+ injections are not FDA-approved for any specific indication and are typically obtained through compounding pharmacies outside standard clinical oversight. The creator's route-of-administration hierarchy reflects basic pharmacokinetic logic, but no published human trials have directly compared sub-Q versus IM versus IV NAD+ on efficacy or absorption outcomes. Any perceived effects within days of starting injections should be interpreted cautiously given strong expectation bias inherent in unblinded self-experimentation.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
NAD+ Peptide Complex access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For NAD+ injections for energy and aging: what the evidence shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis
Supports careful discussion of semaglutide in NASH-related cirrhosis without overstating outcomes.
PubMed
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis
Used for liver-disease pages where semaglutide appears in exploratory NASH combination research.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
NAD+ Peptide Complex is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this nad+ video claims cluster
Best for searchers separating NAD+ longevity marketing from practical metabolic and safety questions.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "NAD+ injections for energy and aging: what the evidence shows" from Kate's GLP Journey. We read the clip as a Peptide social video fact-checks claim about NAD+ Peptide Complex, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: NAD+ injections are not FDA-approved for any specific indication and are typically obtained through compounding pharmacies outside standard clinical oversight.
The reason this review is not generic is the source wording and the canonical claim label "peptides replying to kristen nad injections sub q im or iv myjourney." In this clip, the useful excerpt is: "So the NAD injections that I'm taking were recommended to be done intermuscular." That wording changes the review because it points to NAD+ Peptide Complex safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference (2025), Discontinuing glucagon-like peptide-1 receptor agonists and body habitus (2025), and Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition (2025), plus the creator's own wording. NAD+ Peptide Complex still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
NAD+ injections are not FDA-approved for any specific indication and are typically obtained through compounding pharmacies outside standard clinical oversight.
FormBlends verdict
NAD+ Peptide Complex safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the NAD+ Peptide Complex guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- NAD+ injections are not FDA-approved for any specific indication and are typically obtained through compounding pharmacies outside standard clinical oversight. The creator's route-of-administration hierarchy reflects basic pharmacokinetic logic, but no published human trials have directly compared sub-Q versus IM versus IV NAD+ on efficacy or absorption outcomes. Any perceived effects within days of starting injections should be interpreted cautiously given strong expectation bias inherent in unblinded self-experimentation.
- NAD+ is a coenzyme, not a peptide. It's frequently grouped with peptide biohacking content but belongs to a distinct biochemical category.
- No published randomized human trial has compared sub-Q versus IM versus IV routes for NAD+ absorption or clinical outcomes as of 2024.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- NAD+ Peptide Complex decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the NAD+ Peptide Complex guide, cost path, safety notes, and provider review before acting.
Review NAD+ Peptide ComplexWhat You'll Learn
- NAD+ is a coenzyme, not a peptide. It's frequently grouped with peptide biohacking content but belongs to a distinct biochemical category.
- No published randomized human trial has compared sub-Q versus IM versus IV routes for NAD+ absorption or clinical outcomes as of 2024.
- IV administration offers 100% bioavailability by bypassing gut and liver metabolism, which is the pharmacokinetic basis for its perceived superiority. This is logical but not yet proven superior in clinical outcome data.
- Placebo responses to injections are measurably stronger than to oral interventions (Schedlowski et al., 2015, Pharmacological Reviews), which complicates any self-reported 'I noticed a difference' observation without controls.
- Injectable NAD+ is not FDA-approved for any indication and is typically sourced through compounding pharmacies, meaning product purity and dosing consistency are not federally regulated.
- IV NAD+ infusions carry documented side effects including nausea, flushing, and chest tightness that are less commonly reported with sub-Q or IM routes (Braidy et al., 2019, Antioxidants and Redox Signaling).
- Most peer-reviewed NAD+ research in humans uses oral precursors like NMN or NR, not injectable NAD+. Extrapolating from that literature to injection outcomes requires significant caution.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @lose.weight.with.kate actually say?
The creator said she's taking NAD+ injections that came with instructions for either intramuscular (IM) or subcutaneous (sub-Q) administration. Because she's already familiar with sub-Q from GLP-1 shots, she's starting there. She added that she's "already noticed the difference" and that IM might be more effective, but IV is "definitely the best way" — something she attributes to celebrities — while calling it too expensive and inconvenient for her budget.
This is a pretty honest, experience-first framing. She's not selling anything, and she's clear about what she knows versus what she's heard. That matters when we're evaluating credibility. She's also working with instructions from whoever supplied her injections, which raises its own set of questions about sourcing and oversight.
Does the science back this up?
Partially. The IV-versus-injection hierarchy she describes has some biological plausibility, but the human evidence is thin across all three routes. Most clinical research on NAD+ precursors uses oral formulations, not injections, and head-to-head comparison studies between administration routes in humans basically don't exist yet.
NAD+ itself does not survive oral ingestion well because it's broken down in the gut before reaching systemic circulation. That's the argument for injectable routes. A 2023 review by Covarrubias et al. in Nature Aging noted that while NAD+ boosting strategies show metabolic and neuroprotective signals in animal models, translation to human outcomes remains early-stage. IV infusions do bypass first-pass metabolism entirely, which is the pharmacokinetic argument for their superiority. But whether sub-Q absorption is meaningfully inferior to IM for NAD+ specifically has not been tested in any published randomized trial. The creator's claim that IM is more effective than sub-Q is biologically reasonable but not yet evidence-confirmed.
What did they get wrong (or right)?
She got the general hierarchy roughly right on pharmacokinetic logic, even if she didn't know the mechanism. IV does deliver the fastest, most complete absorption. IM generally absorbs faster than sub-Q because muscle tissue is more vascularized. That part checks out as plausible science.
Where she's on shakier ground: saying she's "already noticed the difference" after starting sub-Q injections. That's a personal observation with no baseline measurement, no control, and a strong expectation effect baked in. This is not a criticism unique to her. It's the core problem with self-reported outcomes in unblinded, uncontrolled self-experimentation. The placebo response to injections specifically is well-documented and tends to be stronger than for oral interventions (Schedlowski et al., 2015, Pharmacological Reviews).
She also frames IV as what "all the celebrities do," which is a credibility appeal that doesn't mean much scientifically. IV NAD+ clinics are a wellness industry product, not an FDA-regulated therapy with a proven outcomes record.
What should you actually know?
A few things worth understanding if you're looking at NAD+ injections yourself. First, NAD+ is not a peptide despite being grouped in peptide-adjacent biohacking content. It's a coenzyme. Second, injectable NAD+ sits outside FDA-approved indications and is typically administered through compounding pharmacies or grey-market suppliers, which means quality control varies significantly. Third, IV NAD+ infusions are associated with side effects including nausea, chest tightness, and flushing, which are less commonly reported with IM or sub-Q routes (Braidy et al., 2019, Antioxidants and Redox Signaling).
The honest summary: the route-of-administration logic the creator outlines is pharmacologically coherent. But the idea that any route of NAD+ supplementation produces a noticeable subjective effect within days is not well-supported by controlled human data. If you're considering this, that conversation belongs with a licensed clinician who can assess your individual situation, not a TikTok comment thread.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Kate’s GLP Journey · TikTok creator
1.6K views on this video
Replying to @Kristen NAD+ Injections SUB-Q, IM or IV? 🩷💕🫶 #myjourney #nad #glowup #glowupjourney #peptide #biohacking #selfimprovement #glp1
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about nad+?
NAD+ is a coenzyme, not a peptide. It's frequently grouped with peptide biohacking content but belongs to a distinct biochemical category.
What does the video say about no published randomized human trial has compared sub-q versus im?
No published randomized human trial has compared sub-Q versus IM versus IV routes for NAD+ absorption or clinical outcomes as of 2024.
What does the video say about iv administration offers 100% bioavailability by bypassing gut?
IV administration offers 100% bioavailability by bypassing gut and liver metabolism, which is the pharmacokinetic basis for its perceived superiority. This is logical but not yet proven superior in clinical outcome data.
What does the video say about placebo responses to injections?
Placebo responses to injections are measurably stronger than to oral interventions (Schedlowski et al., 2015, Pharmacological Reviews), which complicates any self-reported 'I noticed a difference' observation without controls.
What does the video say about injectable nad+?
Injectable NAD+ is not FDA-approved for any indication and is typically sourced through compounding pharmacies, meaning product purity and dosing consistency are not federally regulated.
What does the video say about iv nad+ infusions carry documented side effects including nausea, flushing,?
IV NAD+ infusions carry documented side effects including nausea, flushing, and chest tightness that are less commonly reported with sub-Q or IM routes (Braidy et al., 2019, Antioxidants and Redox Signaling).
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Kate’s GLP Journey, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.